Overexpression of tyrosine kinase receptors (RTKs), namely EGFR, PDGFR, VEGFR, and FGFR, and their ligands is among the most frequent alterations in glioma tumorigenesis, leading to aberrant activation of their downstream molecular pathways [18,59]. The gene discussed is KDR; the disease is central nervous system cancer.